Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With...
OsteoporosisThis study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration...
Low Bone Mineral DensityAn Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Post-Menopausal OsteopeniaThis 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
OsteoporosisAAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.
Heartland Osteoporosis Prevention Study
OsteopeniaThe purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calcium and vitamin D plus participate in bone-loading exercises. Our central hypothesis is that improvements in bone health will be greater in women randomized to bone-loading exercises with calcium and vitamin D compared to women who take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium...
Primary HyperparathyroidismOsteopenia1 morePatients with primary hyperparathyroidism (pHPT) with osteopenia and osteoporosis are treated with strontium ranelate/Ca+Vitamin-D or placebo/Ca+Vitamin D after successful surgical treatment of pHPT. Strontium ranelate/Ca + Vitamin-D helps to regain bone mass in patients with osteopenia or osteoporosis after successful parathyroidectomy for pHPT and results in higher gain of BMD than placebo treated patients.
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate...
OsteoporosisOsteopeniaThe purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects receiving alendronate sodium by more than a pre-specified non-inferiority margin.
Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention
OsteopeniaComplications of Heart-lung Transplant1 moreThe purpose of this trial is to see whether zoledronic acid is better than pamidronate to treat low bone density in heart and lung transplant patients.
Study to Evaluate the PK, PD and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low...
Postmenopausal OsteoporosisA 29 days study to evaluate the usability of the abaloparatide-sMTS
A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant
Implant Clinical SurvivalDental Implant Bone LossThe current prospective clinical study's aim is to determine ABT's ICE implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of ICE implants.